SCHEMBL24252743

SCHEMBL24252743

COc1ccc(B(O)O)cc1-c1cnc2c(N)nccc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLG P00747 1/20 0.41
F12 P00748 1/20 0.41
F11 P03951 1/20 0.41
KLKB1 P03952 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
PDGFRB P09619 2/20 0.37
PDGFRA P16234 2/20 0.37
NTRK1 P04629 1/20 0.36
FYN P06241 7/20 0.36
CHEK2 O96017 3/20 0.35
CHEK1 O14757 1/20 0.35
JAK2 O60674 1/20 0.34
JAK1 P23458 1/20 0.34
TYK2 P29597 1/20 0.34
KDR P35968 1/20 0.34
JAK3 P52333 1/20 0.34
AURKB Q96GD4 1/20 0.34
TGFBR1 P36897 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL25267017 0.94 PLG (0.37) PLGF12F11KLKB1PRSS1
Formic Acid SCHEMBL30452053 0.94 PLG (0.37) PLGF12F11KLKB1PRSS1
SCHEMBL25215695 0.86 CHEK2 (0.33) PDGFRBPDGFRANTRK1FYNCHEK2
SCHEMBL26775949 0.84 DHFR (0.37) PLGF12F11KLKB1PRSS1
SCHEMBL24252941 0.82 F12 (0.60) PLGF12F11KLKB1PRSS1
SCHEMBL26771329 0.80 DHFR (0.36) PLGF12F11KLKB1PRSS1
SCHEMBL30467740 0.80 PDGFRB (0.44) PDGFRBPDGFRANTRK1
SCHEMBL24252628 0.80 PDGFRB (0.44) PDGFRBPDGFRANTRK1
SCHEMBL30451479 0.77 PDE10A (0.42) PDGFRBPDGFRANTRK1KDR
SCHEMBL24252629 0.77 PDE10A (0.42) PDGFRBPDGFRANTRK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 PLG 260/4885F12 29/4885F11 117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.